Fortra GoAnywhere MFT Deserialization of Untrusted Data Vulnerability (CVE-2025-10035)

Fortra GoAnywhere MFT contains a deserialization of untrusted data vulnerability allows an actor with a validly forged license response signature to deserialize an arbitrary actor-controlled object, possibly leading to command injection.

Published Sep 18, 2025 · Updated May 29, 2026

X LinkedIn

Why patchRisk explained in plain English

Worst-case scenarioIf unpatched

A remote attacker, without authentication, can achieve full data confidentiality loss, arbitrary modification of data, complete denial of service or system unavailability. CISA has confirmed use of this vulnerability in known ransomware campaigns — treat as high priority for remediation. Federal agencies are required to remediate by 2025-10-20 under CISA BOD 22-01.

How the attack worksNo clicks needed

This is a Command Injection (CWE-77) vulnerability in Fortra GoAnywhere MFT. A deserialization vulnerability in the License Servlet of Fortra's GoAnywhere MFT allows an actor with a validly forged license response signature to deserialize an arbitrary actor-controlled object, possibly leading to command injection. Exploitation requires remote network access, low attack complexity, no authentication required, and no user interaction required.

📧

Phishing link

→

🖼

Malicious file

🔓

Server compromised

Am I affected?Quick check

Probably yes if any of these apply:

●IT Security

●Running goanywhere managed file transfer: v < 7.6.3, 7.7.0 ≤ v < 7.8.4

Real-world incidentsWhat we've seen

CISA confirms this CVE has been used in known ransomware campaigns. Added to the KEV catalog on 2025-09-29; federal agencies required to remediate by 2025-10-20.

How to patch

Manual remediation steps

Apply the Vendor Patch

This vulnerability is in the CISA Known Exploited Vulnerabilities catalog — apply the vendor's security update as soon as possible.

CISA required action: Apply mitigations per vendor instructions, follow applicable BOD 22-01 guidance for cloud services, or discontinue use of the product if mitigations are unavailable.